TORRENT PHARMACEUTICALS LTD. - 500420 - Disclosure Pursuant To Regulation 30 Read With Schedule III And Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements), 2015, ("Listing Regulations")
Disclosure pursuant to Regulation 30 read with Schedule III and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), 2015, ("Listing Regulations") TORRENT PHARMACEUTICALS LTD. - 500420 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 08-Feb-19 and BSE and NSE Circulars dated 16-Mar-23 and 10-Apr-23 respectively, kindly find enclosed herewith Annual Secretarial Compliance Report for the year ended on 31-Mar-23 issued by M/s. M. C. Gupta & Co., Practicing Company Secretaries, Ahmedabad. Kindly take note of the above. TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
We would like to inform that Hon''ble National Company Law Tribunal, Ahmedabad Bench ("NCLT"), vide its Order dated 17th May, 2023, has sanctioned the Scheme of Arrangement in the nature of Amalgamation between Curatio Health Care (I) Private Limited, a wholly owned subsidiary of the Company with Torrent Pharmaceuticals Limited and their respective shareholders and creditors ("Scheme") pursuant to the provisions of Section 230 to 232 and other applicable provisions of the Companies Act, 2013 and rules made thereunder. A copy of the said Order is available on the website of the Company. The above is in continuation to our earlier communication dated 21-Dec-22 intimating the approval of the said Scheme of Amalgamation by the Board of Directors of the Company in its meeting held on 21-Dec-22. The Scheme will become effective upon filing of the said Order with the Registrar of Companies, Gujarat. Kindly take note of the above.
Torrent Pharma forms Bullish Harami pattern. Will it reclaim record high?
After hitting a high around Rs 1,680, the stock has been into consolidation for more than couple of weeks and has been struggling for breakout the same high. If the said level breaks out in coming days, then the stock can march towards its record high of Rs 1,750, experts feel. TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Post Quarterly Financial Result Conference call with investors / analyst We hereby inform that the Company has scheduled a teleconference with Investors / Analyst on 30th May, 2023 at 06:00 P.M. to discuss the financial performance of the Company for the quarter and year ended 31st March, 2023. TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 ,inter alia, to consider and approve We would like to inform you that: 1. A meeting of the Board of Directors will be held on Tuesday, 30-May-23, inter alia, to consider and approve the Audited Financial Results of the Company for the year ended on 31-Mar-23. 2. In the above meeting, the Board would also consider the following: i. Recommendation of final dividend, if any, on the equity shares of the Company, for the year 2022-23. ii. Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes. If approved by the Board of Directors, the said item will be placed for Shareholders'' approval in the ensuing Annual General Meeting. Kindly take note of the above. TORRENT PHARMACEUTICALS LTD. - 500420 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company TORRENT PHARMACEUTICALS LTD. 2 CIN NO. L24230GJ1972PLC002126 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2022-23, 2023-24, 2024-25 5 Incremental borrowing done in FY (T)(a) 1395.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 348.75 7 Actual borrowing done through debt securities in FY (T)(c) 500.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) NIL 8Quantum of (d), which has been met from (c)(e)* NA 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* NIL Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2021-22, 2022-23, 2023-24 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Chintan M TrivediDesignation :-Company Secretary Name of the Chief Financial Officer :- Sudhir Menon Designation : -Chief Financial Officer Date: 26/04/2023 TORRENT PHARMACEUTICALS LTD. - 500420 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyTORRENT PHARMACEUTICALS LTD. 2CIN NO.L24230GJ1972PLC002126 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 3368.00 4Highest Credit Rating during the previous FY AA+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: Chintan M Trivedi Designation: Company Secretary EmailId: InvestorServices@TorrentPharma.com Name of the Chief Financial Officer: Sudhir Menon Designation: Chief Financial Officer EmailId: InvestorServices@TorrentPharma.com Date: 26/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.